



Investor and Media Inquiries:

David Pitts
Argot Partners
212-600-1902

Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717

Sunesis to Present at the 13th Annual BIO CEO & Investor Conference

SOUTH SAN FRANCISCO, Calif., (February 8, 2011) – Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be presenting at the upcoming 13th Annual BIO CEO & Investor Conference on Tuesday, February 15, 2011 at 9:30 A.M. Eastern Time at the Waldorf Astoria Hotel in New York City.

A live webcast of the presentation will be available on the Sunesis website at <http://ir.sunesis.com>. A replay of the webcast will be archived on the “Calendar of Events” page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit <http://www.sunesis.com>.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.